Full-Time

Refractive Laser Consumable Sales Specialist

Posted on 5/9/2026

Zeiss

Zeiss

1,001-5,000 employees

Manufactures high-precision optical instruments and devices

Compensation Overview

$80k/yr

+ Commission

Company Does Not Provide H1B Sponsorship

California, USA

Hybrid

Category
Sales & Account Management (2)
,
Required Skills
Sales
Forecasting
Data Analysis
Requirements
  • Bachelor’s degree preferred (Business, Life Sciences, or related field preferred) or equivalent experience
  • Minimum 3–5 years of successful medical device sales experience, ideally in ophthalmology, refractive surgery, or capital equipment/consumables
  • Proven track record of growing utilization and driving revenue in complex, relationship-driven accounts
  • Experience calling on refractive surgeons, practice administrators, and optometric co-management networks is highly preferred
  • Exceptional account management and consultative selling skills
  • Strong business acumen with the ability to analyze utilization data and build compelling growth plans
  • High energy, resilience, and a farming mentality
  • Outstanding verbal and written communication skills
  • Ability to thrive in a team environment while maintaining individual accountability
Responsibilities
  • Own a portfolio of key refractive accounts and deliver consistent, above-plan revenue growth through the sale and increased utilization of ZEISS refractive consumables (SMILE, SMILE pro, LASIK flap, ICR and MEL90)
  • Partner with account surgeons, practice administrators, and staff to identify barriers to procedure growth and implement targeted action plans that drive higher case volume and consumable consumption
  • Work hand-in-hand with Refractive Sales Representatives and Clinical Applications teams to deliver seamless, high-value support to customers. Co-develop and execute strategic account plans that align clinical excellence with commercial results
  • Build and maintain strong, multi-level relationships within each account. Conduct regular business reviews, utilization audits, and performance coaching sessions to ensure ZEISS is the preferred and highest-volume platform
  • Continuously monitor account performance, competitive activity, and market trends. Proactively surface expansion opportunities (new surgeons, additional lasers, practice growth initiatives) and convert them into revenue
  • Maintain a strong, visible presence in the field. Travel extensively (60–75%) within the territory to support live cases, conduct training, deliver in-service programs, and build personal relationships with key decision-makers
  • Provide accurate, timely forecasts and pipeline updates. Track and report key performance metrics (utilization rates, revenue per account, case growth) in CRM and monthly business reviews

ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Shop-floor metrology adoption accelerates CMM sales into automotive, aerospace, heavy equipment sectors.
  • Cloud-based Collaborative Care extends subscription licensing model to industrial quality networks.
  • MICOR 700 ultrasound-free handheld device opens portable metrology market in surgical applications.

What critics are saying

  • ASML's EUV lithography monopoly threatens ZEISS semiconductor optics segment revenue sustainability.
  • VisioGen AI platform faces FDA liability exposure if AI responses cause patient harm.
  • Ransomware attack on ZEISS Health Data Platform halts clinical workflows across customer sites.

What makes Zeiss unique

  • ZEISS dominates precision optics across semiconductor, medical, and industrial segments globally.
  • ARTEVO 850 microscope offers 60% depth-of-field increase with true 3D visualization capability.
  • VisioGen AI platform provides human-verified patient engagement integrated into ophthalmology workflows.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Zeiss who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

PR Newswire
Apr 2nd, 2026
ZEISS unveils AI-powered patient platform and enhanced IOL tools at ASCRS

ZEISS has unveiled new digital, AI and surgical innovations for cataract and refractive workflows at the ASCRS conference. The medical technology company is expanding its US cataract portfolio with new irrigation/aspiration handpieces compatible with the DORC EVA NEXUS surgical system, alongside enhanced IOL calculation capabilities for the ZEISS IOLMaster 700. ZEISS also launched VisioGen commercially in the US, a human-verified AI patient engagement platform for ophthalmology practices. The platform integrates with clinic websites to capture patient demand around the clock, with AI-assisted responses reviewed by ZEISS-trained optometrists before delivery. The company showcased ZEISS Collaborative Care, a cloud-based application enabling secure data sharing between eye care professionals, and previewed ZEISS CLINIC 360, pending FDA clearance. ZEISS is celebrating 100 years of US operations this year.

PR Newswire
Mar 24th, 2026
ZEISS expands ophthalmic portfolio in Canada with new diagnostic lasers and workflow tools

ZEISS Medical Technology has expanded its ophthalmic workflow portfolio in Canada with new diagnostic, visualisation and therapeutic solutions. The company will showcase the innovations at upcoming Canadian ophthalmology conferences in Ottawa and Montréal. Key additions include ICGA for ZEISS CLARUS 700, offering simultaneous FA and ICG capture for clinical assessment, and ZEISS VISULAS green with selective laser trabeculoplasty for retinal photocoagulation. The company has introduced refraction devices ZEISS VISUREF 600 and ZEISS VISUCORE 500 to streamline diagnostic workflows. ZEISS also launched VISULAS yag, a new-generation therapeutic laser for anterior segment photodisruption within cataract workflows. The ZEISS FORUM subscription package, now available in Canada, offers integrated data management with unlimited device licences and lower upfront costs.

PR Newswire
Feb 23rd, 2026
ZEISS launches Collaborative Care app for eye care professionals with cloud and on-premises options

ZEISS Medical Technology has launched Collaborative Care, a browser-based application enabling eye care professionals to share data securely, refer patients and coordinate clinical care. Built on the ZEISS Health Data Platform, the solution addresses fragmented data sharing and inefficient referral processes in ophthalmic care. The application offers flexible deployment as either a standalone cloud solution or an integrated extension of ZEISS FORUM. Key features include secure exchange of images and reports, streamlined referral workflows with tracking capabilities, and tools for building professional networks between optometrists and ophthalmologists. ZEISS Collaborative Care was demonstrated at industry events in London and Orlando in February and March 2026. The company generated €2,228 million in revenue in fiscal year 2024/25 with 5,784 employees worldwide.

Handelsblatt
Feb 19th, 2026
Custom Surgical raises $4M to develop AI-powered ophthalmology platform

Custom Surgical, a German ophthalmology company, has raised €3.5 million to advance its platform. The funding will support development of AI-powered features including automated image optimisation and assisted triage processes that help determine case urgency and specialist assignment. The company is already developing its first AI-based triage and screening system. The technology aims to provide initial assessments that guide decisions on how urgently cases need attention and which medical professionals should handle them next.

Investors Hangout
Feb 18th, 2026
Mindpeak raises $15.3M Series A to scale AI cancer diagnostic tools

Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.